Jim et al. observed a similar QoL with different ICI regimens (all monotherapy) [34], while anti-PD-1 monotherapy was associated with better QoL compared to anti-PD-1/anti-CTLA-4 combination in survivors with melanoma in the study by Joseph et al. [33]. This evidence concerns the gene CTLA4 and melanoma.